Up-regulation of Serum MIR-130b-3p Level is Associated with Renal Damage in Early Lupus Nephritis

Scientific Reports

Volumn 5, Issue , 2015, Pages

  Wang, Wanpeng ^a   Mou, Shan ^a   Wang, Ling ^a   Zhang, Minfang ^a   Shao, Xinghua ^a   Fang, Wei ^a   Lu, Renhua ^a   Qi, Chaojun ^a   Fan, Zhuping ^a   Cao, Qin ^a   Wang, Qin ^a   Fang, Yan ^a   Ni, Zhaohui ^a  

^a SHANGHAI JIAO TONG UNIVERSITY SCHOOL OF MEDICINE   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ERBB2IP PROTEIN, HUMAN; MICRORNA; MIRN-1233 MICRORNA, HUMAN; MIRN130 MICRORNA, HUMAN; SIGNAL TRANSDUCING ADAPTOR PROTEIN; TRANSFORMING GROWTH FACTOR BETA1;

ADULT; BLOOD; CELL LINE; DRUG EFFECTS; EPITHELIAL MESENCHYMAL TRANSITION; EPITHELIUM CELL; FEMALE; GENE EXPRESSION PROFILING; GENETICS; HUMAN; KIDNEY; KIDNEY TUBULE; LUPUS ERYTHEMATOSUS NEPHRITIS; MALE; METABOLISM; PATHOLOGY; REPRODUCIBILITY; SYSTEMIC LUPUS ERYTHEMATOSUS; UPREGULATION;

ADAPTOR PROTEINS, SIGNAL TRANSDUCING; ADULT; CELL LINE; EPITHELIAL CELLS; EPITHELIAL-MESENCHYMAL TRANSITION; FEMALE; GENE EXPRESSION PROFILING; HUMANS; KIDNEY; KIDNEY TUBULES; LUPUS ERYTHEMATOSUS, SYSTEMIC; LUPUS NEPHRITIS; MALE; MICRORNAS; REPRODUCIBILITY OF RESULTS; TRANSFORMING GROWTH FACTOR BETA1; UP-REGULATION;

EID: 84940491316     PISSN: None     EISSN: 20452322     Source Type: Journal    
DOI: 10.1038/srep12644     Document Type: Article

References (43)

1. Cook, H. T. & Botto, M. Mechanisms of Disease: the complement system and the pathogenesis of systemic lupus erythematosus. Nature clinical practice. Rheumatology 2, 330-337, doi: 10.1038/ncprheum0191 (2006).
2. Moulton, V. R. & Tsokos, G. C. Abnormalities of T cell signaling in systemic lupus erythematosus. Arthritis research & therapy 13, 207, doi: 10.1186/ar3251 (2011).
3. Dorner, T., Giesecke, C. & Lipsky, P. E. Mechanisms of B cell autoimmunity in SLE. Arthritis research & therapy 13, 243, doi: 10.1186/ar3433 (2011).
4. Yung, S. & Chan, T. M. Autoantibodies and resident renal cells in the pathogenesis of lupus nephritis: getting to know the unknown. Clinical & developmental immunology 2012, 139365, doi: 10.1155/2012/139365 (2012).
5. Thomas, G. et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis. Arthritis Rheumatol 66, 2503-2511, doi: 10.1002/art.38731 (2014).
6. Aran, A. A. & Putterman, C. Treatment of lupus nephritis: facing the era of immunotherapy. Panminerva Med 50, 235-245 (2008).
7. Meister, G. & Tuschl, T. Mechanisms of gene silencing by double-stranded RNA. Nature 431, 343-349, doi: 10.1038/nature02873 (2004).
8. Bartel, D. P. MicroRNAs: genomics, biogenesis, mechanism, and function. Cell 116, 281-297 (2004).
9. Grimson, A. et al. Early origins and evolution of microRNAs and Piwi-interacting RNAs in animals. Nature 455, 1193-1197, doi: 10.1038/nature07415 (2008).
10. Kapsogeorgou, E. K., Gourzi, V. C., Manoussakis, M. N., Moutsopoulos, H. M. & Tzioufas, A. G. Cellular microRNAs (miRNAs) and Sjogren's syndrome: candidate regulators of autoimmune response and autoantigen expression. Journal of autoimmunity 37, 129-135, doi: 10.1016/j.jaut.2011.05.003 (2011).
11. Pauley, K. M. et al. Upregulated miR-146a expression in peripheral blood mononuclear cells from rheumatoid arthritis patients. Arthritis research & therapy 10, R101, doi: 10.1186/ar2493 (2008).
12. Tang, Y. et al. MicroRNA-146A contributes to abnormal activation of the type I interferon pathway in human lupus by targeting the key signaling proteins. Arthritis and rheumatism 60, 1065-1075, doi: 10.1002/art.24436 (2009).
13. Gilad, S. et al. Serum microRNAs are promising novel biomarkers. PLoS One 3, e3148, doi: 10.1371/journal.pone.0003148 (2008).
14. Glowacki, F. et al. Increased circulating miR-21 levels are associated with kidney fibrosis. PLoS One 8, e58014, doi: 10.1371/ journal.pone.0058014 (2013).
15. Wang, G. et al. Serum and urinary cell-free MiR-146a and MiR-155 in patients with systemic lupus erythematosus. The Journal of rheumatology 37, 2516-2522, doi: 10.3899/jrheum.100308 (2010).
16. Zhang, Y. et al. Secreted monocytic miR-150 enhances targeted endothelial cell migration. Mol Cell 39, 133-144, doi: 10.1016/j. molcel.2010.06.010 (2010).
17. Mitchell, P. S. et al. Circulating microRNAs as stable blood-based markers for cancer detection. Proceedings of the National Academy of Sciences of the United States of America 105, 10513-10518, doi: 10.1073/pnas.0804549105 (2008).
18. Brase, J. C., Wuttig, D., Kuner, R. & Sultmann, H. Serum microRNAs as non-invasive biomarkers for cancer. Mol Cancer 9, 306, doi: 10.1186/1476-4598-9-306 (2010).
19. Carlsen, A. L. et al. Circulating microRNA expression profiles associated with systemic lupus erythematosus. Arthritis and rheumatism 65, 1324-1334, doi: 10.1002/art.37890 (2013).
20. Zhou, H. et al. miR-150 promotes renal fibrosis in lupus nephritis by downregulating SOCS1. J Am Soc Nephrol 24, 1073-1087, doi: 10.1681/ASN.2012080849 (2013).
21. Bombardier, C., Gladman, D. D., Urowitz, M. B., Caron, D. & Chang, C. H. Derivation of the SLEDAI. A disease activity index for lupus patients. The Committee on Prognosis Studies in SLE. Arthritis and rheumatism 35, 630-640 (1992).
22. Weening, J. J. et al. The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15, 241-250 (2004).
23. Qiu, L. J. et al. Decreased SOCS1 mRNA expression levels in peripheral blood mononuclear cells from patients with systemic lupus erythematosus in a Chinese population. Clin Exp Med, doi: 10.1007/s10238-014-0309-2 (2014).
24. Wang, Y. C. et al. Circulating miR-130b mediates metabolic crosstalk between fat and muscle in overweight/obesity. Diabetologia 56, 2275-2285, doi: 10.1007/s00125-013-2996-8 (2013).
25. Zhou, Q. et al. Erbin inhibits TGF-beta1-induced EMT in renal tubular epithelial cells through an ERK-dependent pathway. J Mol Med (Berl) 90, 563-574, doi: 10.1007/s00109-011-0833-4 (2012).
26. Wittmann, J. & Jack, H. M. Serum microRNAs as powerful cancer biomarkers. Biochim Biophys Acta 1806, 200-207, doi: 10.1016/j.bbcan.2010.07.002 (2010).
27. Shrivastava, S. et al. Up-regulation of circulating miR-20a is correlated with hepatitis C virus-mediated liver disease progression. Hepatology 58, 863-871, doi: 10.1002/hep.26296 (2013).
28. Karpetsky, T. P., Humphrey, R. L. & Levy, C. C. Influence of renal insufficiency on levels of serum ribonuclease in patients with multiple myeloma. J Natl Cancer Inst 58, 875-880 (1977).
29. Humphrey, R. L., Karpetsky, T. P., Neuwelt, E. A. & Levy, C. C. Levels of serum ribonuclease as an indicator of renal insufficiency in patients with leukemia. Cancer Res 37, 2015-2022 (1977).
30. Rabinovitch, M., Liberman, B. & Fausto, N. Plasma ribonuclease activity in human uremia. J Lab Clin Med 53, 563-568 (1959).
31. Neal, C. S. et al. Circulating microRNA expression is reduced in chronic kidney disease. Nephrol Dial Transplant 26, 3794-3802, doi: 10.1093/ndt/gfr485 (2011).
32. Gatti, S. et al. Microvesicles derived from human adult mesenchymal stem cells protect against ischaemia-reperfusion-induced acute and chronic kidney injury. Nephrol Dial Transplant 26, 1474-1483, doi: 10.1093/ndt/gfr015 (2011).
33. Reis, L. A. et al. Bone marrow-derived mesenchymal stem cells repaired but did not prevent gentamicin-induced acute kidney injury through paracrine effects in rats. PLoS One 7, e44092, doi: 10.1371/journal.pone.0044092 (2012).
34. Bitzer, M., Ben-Dov, I. Z. & Thum, T. Microparticles and microRNAs of endothelial progenitor cells ameliorate acute kidney injury. Kidney Int 82, 375-377, doi: 10.1038/ki.2012.152 (2012).
35. Yip, L. et al. MicroRNA signature distinguishes the degree of aggressiveness of papillary thyroid carcinoma. Ann Surg Oncol 18, 2035-2041, doi: 10.1245/s10434-011-1733-0 (2011).
36. Zong, C., Wang, J. & Shi, T. M. MicroRNA 130b enhances drug resistance in human ovarian cancer cells. Tumour Biol 35, 12151-12156, doi: 10.1007/s13277-014-2520-x (2014).
37. Colangelo, T. et al. MicroRNA-130b promotes tumor development and is associated with poor prognosis in colorectal cancer. Neoplasia 15, 1218-1231 (2013).
38. Ress, A. & Moelling, K. Interaction partners of the PDZ domain of erbin. Protein Pept Lett 13, 877-881 (2006).
39. McDonald, C. et al. A role for Erbin in the regulation of Nod2-dependent NF-kappaB signaling. J Biol Chem 280, 40301-40309, doi: 10.1074/jbc.M508538200 (2005).
40. Dai, F. et al. Erbin inhibits transforming growth factor beta signaling through a novel Smad-interacting domain. Mol Cell Biol 27, 6183-6194, doi: 10.1128/MCB.00132-07 (2007).
41. Pan, S., Yang, X., Jia, Y., Li, R. & Zhao, R. Microvesicle-shuttled miR-130b reduces fat deposition in recipient primary cultured porcine adipocytes by inhibiting PPAR-g expression. J Cell Physiol 229, 631-639, doi: 10.1002/jcp.24486 (2014).
42. Kanjanabuch, T. et al. PPAR-gamma agonist protects podocytes from injury. Kidney Int 71, 1232-1239, doi: 10.1038/sj.ki.5002248 (2007).
43. Zuo, Y. et al. Protective effects of PPARgamma agonist in acute nephrotic syndrome. Nephrol Dial Transplant 27, 174-181, doi: 10.1093/ndt/gfr240 (2012).